Altamira Therapeutics (CYTO) has released an update.
Altamira Therapeutics Ltd. has issued a pre-funded common share purchase warrant, enabling holders to subscribe and purchase common shares from the company from September 19, 2024, until the warrant’s full exercise. The purchase price per share is predetermined as described in the Warrant, with the exercise price largely pre-funded to the company, requiring only a nominal additional payment upon exercise.
For further insights into CYTO stock, check out TipRanks’ Stock Analysis page.
